Progyny, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Progyny, Inc. payments for repurchase of common stock for the quarter ending 2026-06-30 was $30.02M.
- Progyny, Inc. payments for repurchase of common stock for the quarter ending 2026-03-31 was $118.61M.
- Progyny, Inc. payments for repurchase of common stock for the quarter ending 2025-12-31 was $81.66M, a 48.19% increase year-over-year.
- Progyny, Inc. payments for repurchase of common stock for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Progyny, Inc. payments for repurchase of common stock for fiscal 2025 was $81.66M, a 72.81% decline from fiscal 2024.
- Progyny, Inc. payments for repurchase of common stock for fiscal 2024 was $300.28M.
- Progyny, Inc. payments for repurchase of common stock for fiscal 2023 was $0.00.
- Progyny, Inc. payments for repurchase of common stock for fiscal 2022 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $30.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $230.29M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $118.61M 10-Q · filed 2026-05-08 | $200.26M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $81.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $81.66M 10-K · filed 2026-02-27 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $55.10M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $116.56M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-08 | $276.51M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $55.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $300.28M 10-K · filed 2026-02-27 |
| 2024-09-30 | $61.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $245.18M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $159.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $183.72M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $23.76M 10-Q · filed 2025-05-09 | $23.76M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | |
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 | |
| 2019-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $185.00K 10-K · filed 2022-03-01 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.21M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |